Abstract
Background & Aims: Non-alcoholic steatohepatitis (NASH) is an independent risk factor for cardiovascular disease (CVD) morbidity after liver transplantation, but its impact on CVD mortality is unknown. We sought to assess the impact of NASH on CVD mortality after liver transplantation and to predict which NASH recipients are at highest risk of a CVD-related death following a liver transplant. Methods: Using the Organ Procurement and Transplantation Network database, we examined associations between NASH and post-liver transplant CVD mortality, defined as primary cause of death from thromboembolism, arrhythmia, heart failure, myocardial infarction or stroke. A physician panel reviewed cause of death. Results: Of 48 360 liver transplants (2/2002-12/2011), 5057 (10.5%) were performed for NASH cirrhosis. NASH recipients were more likely to be older, female, obese, diabetic and have history of renal failure or prior CVD vs. non-NASH (P < 0.001 for all). Although there was no difference in overall all-cause mortality (log-rank P = 0.96), both early (30-day) and long-term CVD-specific mortality was increased among NASH recipients (Odds ratio = 1.30, 95% Confidence interval (CI): 1.02-1.66; Hazard ratio = 1.42, 95% CI: 1.07-1.41 respectively). These associations were no longer significant after adjustment for pre-transplant diabetes, renal impairment or CVD. A risk score comprising age ≥55, male sex, diabetes and renal impairment was developed for prediction of post-liver transplant CVD mortality (c-statistic 0.60). Conclusion: NASH recipients have an increased risk of CVD mortality after liver transplantation explained by a high prevalence of comorbid cardiometabolic risk factors that in aggregate identify those at highest risk of post-transplant CVD mortality.
Original language | English (US) |
---|---|
Pages (from-to) | 2575-2583 |
Number of pages | 9 |
Journal | Liver International |
Volume | 35 |
Issue number | 12 |
DOIs | |
State | Published - Dec 1 2015 |
Funding
The data reported here have been supplied by the United Network for Organ Sharing (UNOS) as a contractor for the Organ Procurement and Transplantation Network (OPTN). The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy of or interpretation by the OPTN or the U.S. Government. Financial support: Dr VanWagner was supported by the National Institutes of Health (1 F32 HL116151-01), the American Liver Foundation (New York, NY), the American Association for the Study of Liver Diseases (AASLD) foundation and the Alpha Omega Alpha (AOA) Medical Honor Society Foundation. The sponsors played no role in the development of writing of this manuscript. Conflict of interest: The authors do not have any disclosures to report.
Keywords
- Fatty liver
- Heart disease
- Mortality
- NAFLD
- NASH
ASJC Scopus subject areas
- Hepatology